Real-world data collection for lymphoma and patient survival

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The REALYSA cohort is an observational platform designed to gather real-world epidemiological data on various types of lymphoma, including Diffuse Large B-cell Lymphoma and Follicular Lymphoma. This study aims to enhance prognostic understanding by integrating clinical, biological, and epidemiological data to identify factors influencing treatment outcomes and long-term survivorship. It also seeks to document treatment effectiveness in real-life settings and address socio-economic impacts on patients. By following lymphoma patients over time, the study will provide insights into quality of life and potential long-term sequelae.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signature of the consent form for participation in the REALYSA cohort
* Aged over 18 at the time of inclusion
* Diagnosed with lymphoma in the last 6 months (180 days)
* Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma

Exclusion Criteria:

* Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)
* Documented HIV infection
* Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:

  * Chronic lymphocytic leukemia/small lymphocytic lymphoma
  * Hairy cell leukemia and variant
  * Lymphoplasmacytic lymphoma
  * Waldenström macroglobulinemia
  * Primary DLBCL of the central nervous system (CNS)
  * T-cell large granular lymphocytic leukemia
  * Chronic lymphoproliferative disorder of NK cells
  * Mycosis fungoides
  * Sézary syndrome
  * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
  * Post-transplant lymphoproliferative disorders (PTLD)

Where it's running

• Unité d'Hématologie Clinique, CH D'ARRAS
  Arras, France Recruiting
• Service d'Hématologie, CHU Jean Minjoz
  Besançon, France Recruiting
• Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine
  Bordeaux, France Recruiting
• Institut Bergonié
  Bordeaux, France Recruiting
• Centre Hospitalier Pierre Oudot
  Bourgoin, France Recruiting
• Service d'Hématologie, Institut d'Hématologie de Basse Normandie
  Caen, France Recruiting

Study contacts

• Study coordinator: Hervé Ghesquières, MD
• Email: herve.ghesquieres@chu-lyon.fr
• Phone: 04 78 86 43 40

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma

  This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.

  Recruiting at 6 sites Phase 1 LTZ Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07121946

• Testing EXS73565 for patients with relapsed or refractory B-cell cancers

  This study is testing a new oral medication called EXS73565 to see if it can help adults with B-cell cancers that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1 Exscientia AI Limited · Tbilisi and 16 other locations · NCT06980116

• Registry platform for patients with blood cancers in Germany

  This study is setting up a national registry to collect information from patients with blood cancers in Germany to see how well different treatments work and what patients need.

  Recruiting iOMEDICO AG · Freiburg im Breisgau · NCT06043011

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.